OncoResponse
is a Washington-based biotechnology company that researches and develops immunotherapies for the treatment of cancer... Read moreOncoResponse
is a Washington-based biotechnology company that researches and develops immunotherapies for the treatment of cancer... Read more
News
Nov 08, 2024
Clinical Trials Arena
OncoResponse: OncoResponse reports data from Phase I solid tumour treatment trial
Nov 07, 2024
PR Newswire
Press Release: OncoResponse : OncoResponse Announces Phase 1 Results of the Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer
Jun 05, 2023
Pulse2.0
OncoResponse: OncoResponse: $13 Million Grant And $14 Million In Funding Received
May 23, 2023
The Business Journals: Seattle
OncoResponse: Cancer-focused biotech startup OncoResponse raises $27M
May 22, 2023
Startup Around
OncoResponse: OncoResponse lands $27M to advance development of antibody-based treatments for cancer
May 19, 2023
Citybizlist
OncoResponse: OncoResponse Raises $14M in Funding
May 19, 2023
Pharamceutical Technology
OncoResponse: OncoResponse receives CPRIT grant to advance OR502
May 18, 2023
VC News Daily
OncoResponse: OncoResponse Scoops Up $14M
Mar 15, 2023
PR Newswire
Press Release: OncoResponse : OncoResponse Announces Presentation of Preclinical Data on Dual Antibodies Targeting LILRB1 and LILRB2 at American Association for Cancer Research Annual Meeting 2023 (AACR 2023)
Nov 11, 2022
StreetInsider
Press Release: OncoResponse : OncoResponse Announces Preclinical Data Highlighting OR2805 Discovery from Elite Responder Platform and OR502 anti-LILRB2 Antibody at SITC 2022
OncoResponse Competitors
1
2
3
4
5
6
7
8
9
10